MAPT and Alzheimer disease: In the intracerebral (i.e.)Streptozotocin (STZ) model of sporadic AD and the 5XFAD model of genetic AD [3,28,40], treatment with a PPAR-δ agonist prevented or reduced deficits in spatial learning and memory, neurodegeneration, and brain levels of amyloid-β peptide cleavage product of the amyloid precursor protein (Aβ), phospho-tau (pTau), and oxidative stress [28].